Skip to main content Skip to navigation
BUV661 Mouse Anti-Human CD11b
BUV661 Mouse Anti-Human CD11b
Multiparameter flow cytometric analysis using BD OptiBuild™ BUV661 Mouse Anti-Human CD11b antibody (Cat. No. 750064) on Human peripheral blood. Samples were acquired on the BD FACSymphony™ A5 SE Cell Analyzer.
Multiparameter flow cytometric analysis using BD OptiBuild™ BUV661 Mouse Anti-Human CD11b antibody (Cat. No. 750064) on Human peripheral blood. Samples were acquired on the BD FACSymphony™ A5 SE Cell Analyzer.
Product Details
Down Arrow Up Arrow


BD OptiBuild™
MAC-1A; Mac-1; ITGAM; Integrin alpha M; CR3A; CR-3 alpha; Mo1; SLEB6
Human (Tested in Development)
Mouse BALB/c IgG2a, κ
Human peripheral blood T lymphocytes
Flow cytometry (Qualified)
0.2 mg/ml
AB_2874279
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV661 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Ultraviolet 661 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
750064 Rev. 5
Antibody Details
Down Arrow Up Arrow
D12

The D12 monoclonal antibody specifically binds to CD11b which is also known as Integrin alpha M (Integrin αM), Mac-1 subunit alpha (Mac-1a) or complement receptor 3 alpha chain (CR3a). CD11b is encoded by ITGAM (integrin subunit alpha M) and belongs to the integrin alpha subunit gene family. CD11b is expressed as a ~165-kDa type I transmembrane glycoprotein that associates with the ~95-kDa integrin β2 (CD18) to form the heterodimeric CD11b/CD18 (αM/β2) complex which also known as Mac-1 or CR3. CD11b is expressed on monocytes, dendritic cells, granulocytes, as well as on some T cells, B cells, and NK cells. CD11b functions in cell-cell and cell-substrate interactions and is a receptor for multiple ligands including inactivated C3b (iC3b), ICAM-1 (CD54), ICAM-2 (CD102), ICAM-3 (CD50) or fibrinogen. Mac-1 regulates leucocyte adhesion and migration, as well as phagocytosis of opsonized particles.

CAUTION Binding of this CD11b antibody depends on the presence of Ca++. EDTA or ACD, as anticoagulant might affect binding. Using heparin as an anticoagulant or removal of the anticoagulant is recommended.

750064 Rev. 5
Format Details
Down Arrow Up Arrow
BUV661
The BD Horizon Brilliant™ Ultraviolet 661 (BUV661) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 660-nm. BUV661, driven by BD innovation, is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 660-nm (e.g., 670/25 bandpass filter). The acceptor dye can be excited by the Red (628–640-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
BUV661
Ultraviolet 355 nm
350 nm
660 nm
750064 Rev.5
Citations & References
Down Arrow Up Arrow
View product citations for antibody "750064" on CiteAb

Development References (10)

  1. Lanier LL, Phillips JH. A map of the cell surface antigens expressed on resting and activated human natural killer cells. In: Reinherz EL. Ellis L. Reinherz .. et al., ed. Leukocyte typing II. New York: Springer-Verlag; 1986:157-170.
  2. Bernstein ID, Self S. Joint report of the Myeloid Section of the Second International Workshop on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II: Human Myeloid and Hematopoietic Cells. New York, NY: Springer-Verlag; 1986:1-25.
  3. Bray RA, Gottschalk LR, Landay AL, Gebel HM. Differential surface marker expression in patients with CD-16+ lymphoproliferative disorders: in vivo model for NK differentiation.. Hum Immunol. 1987; 19(2):105-15. (Biology). View Reference
  4. Clement LT, Grossi CE, Gartland GL. Morphologic and phenotypic features of the subpopulation of Leu-2+ cells that suppresses B cell differentiation.. J Immunol. 1984; 133(5):2461-8. (Clone-specific: Flow cytometry, Fluorescence activated cell sorting). View Reference
  5. Gebel HM, Kaizer H, Landay AL. Characterization of circulating suppressor T lymphocytes in bone marrow transplant recipients.. Transplantation. 1987; 43(2):258-63. (Biology). View Reference
  6. Landay A, Gartland GL, Clement LT. Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses.. J Immunol. 1983; 131(6):2757-61. (Immunogen: Blocking, Flow cytometry, Fluorescence activated cell sorting, Immunoprecipitation, Radioimmunoassay). View Reference
  7. Patarroyo M, Makgoba MW. Leucocyte adhesion to cells. Molecular basis, physiological relevance, and abnormalities.. Scand J Immunol. 1989; 30(2):129-64. (Biology). View Reference
  8. Repo H, Jansson SE, Leirisalo-Repo M. Anticoagulant selection influences flow cytometric determination of CD11b upregulation in vivo and ex vivo.. J Immunol Methods. 1995; 185(1):65-79. (Clone-specific: Flow cytometry). View Reference
  9. Ross GD, Cain JA, Lachmann PJ. Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b.. J Immunol. 1985; 134(5):3307-15. (Biology). View Reference
  10. Shalekoff S, Page-Shipp L, Tiemessen CT. Effects of anticoagulants and temperature on expression of activation markers CD11b and HLA-DR on human leukocytes.. Clin Diagn Lab Immunol. 1998; 5(5):695-702. (Clone-specific: Flow cytometry). View Reference
View All (10) View Less
750064 Rev. 5

 

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.